Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
Background and Aims. The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IB...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2021/7591141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565679303163904 |
|---|---|
| author | Panu Wetwittayakhlang Farah Albader Petra A Golovics Gustavo Drügg Hahn Talat Bessissow Alain Bitton Waqqas Afif Gary Wild Peter L Lakatos |
| author_facet | Panu Wetwittayakhlang Farah Albader Petra A Golovics Gustavo Drügg Hahn Talat Bessissow Alain Bitton Waqqas Afif Gary Wild Peter L Lakatos |
| author_sort | Panu Wetwittayakhlang |
| collection | DOAJ |
| description | Background and Aims. The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IBD, and risk factors associated with severe COVID-19 or flare of IBD activity. Methods. A consecutive cohort of IBD patients who were diagnosed with COVID-19 infection and followed up at the McGill University Health Care Centre was obtained between March 1, 2020, and April 30, 2021. Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed. Results. A cohort of 3,516 IBD patients was included. 82 patients (2.3%) were diagnosed with COVID-19 infection (median age: 39.0 (IQR 27.8–48.0), 77% with Crohn’s disease, 50% were female). The prevalence of COVID-19 infection in IBD patients was significantly lower compared to the general population in Canada and Quebec (3.5% versus 4.3%, p<0.001). Severe COVID-19 occurred in 6 patients (7.3%); 2 patients (2.4%) died. A flare of IBD post-COVID-19 infection was reported in 8 patients (9.8%) within 3 months. Biologic therapy was held during active COVID-19 infection in 37% of patients. Age ≥55 years (odds ratio (OR): 11.1, 95% CI: 1.8–68.0), systemic corticosteroid use (OR: 4.6, 95% CI: 0.7–30.1), active IBD (OR: 3.8, 95% CI: 0.7–20.8), and comorbidity (OR: 4.9, 95% CI: 0.8–28.6) were factors associated with severe COVID-19. After initial infection, 61% of IBD patients received COVID-19 vaccinations. Conclusion. The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection. |
| format | Article |
| id | doaj-art-d88f9b2cd7d2454b99ee6cfcf7de5bb8 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-d88f9b2cd7d2454b99ee6cfcf7de5bb82025-02-03T01:07:07ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972021-01-01202110.1155/2021/7591141Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel DiseasePanu Wetwittayakhlang0Farah Albader1Petra A Golovics2Gustavo Drügg Hahn3Talat Bessissow4Alain Bitton5Waqqas Afif6Gary Wild7Peter L Lakatos8Division of GastroenterologyDivision of Internal MedicineDivision of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyBackground and Aims. The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IBD, and risk factors associated with severe COVID-19 or flare of IBD activity. Methods. A consecutive cohort of IBD patients who were diagnosed with COVID-19 infection and followed up at the McGill University Health Care Centre was obtained between March 1, 2020, and April 30, 2021. Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed. Results. A cohort of 3,516 IBD patients was included. 82 patients (2.3%) were diagnosed with COVID-19 infection (median age: 39.0 (IQR 27.8–48.0), 77% with Crohn’s disease, 50% were female). The prevalence of COVID-19 infection in IBD patients was significantly lower compared to the general population in Canada and Quebec (3.5% versus 4.3%, p<0.001). Severe COVID-19 occurred in 6 patients (7.3%); 2 patients (2.4%) died. A flare of IBD post-COVID-19 infection was reported in 8 patients (9.8%) within 3 months. Biologic therapy was held during active COVID-19 infection in 37% of patients. Age ≥55 years (odds ratio (OR): 11.1, 95% CI: 1.8–68.0), systemic corticosteroid use (OR: 4.6, 95% CI: 0.7–30.1), active IBD (OR: 3.8, 95% CI: 0.7–20.8), and comorbidity (OR: 4.9, 95% CI: 0.8–28.6) were factors associated with severe COVID-19. After initial infection, 61% of IBD patients received COVID-19 vaccinations. Conclusion. The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection.http://dx.doi.org/10.1155/2021/7591141 |
| spellingShingle | Panu Wetwittayakhlang Farah Albader Petra A Golovics Gustavo Drügg Hahn Talat Bessissow Alain Bitton Waqqas Afif Gary Wild Peter L Lakatos Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease Canadian Journal of Gastroenterology and Hepatology |
| title | Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
| title_full | Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
| title_fullStr | Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
| title_full_unstemmed | Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
| title_short | Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
| title_sort | clinical outcomes of covid 19 and impact on disease course in patients with inflammatory bowel disease |
| url | http://dx.doi.org/10.1155/2021/7591141 |
| work_keys_str_mv | AT panuwetwittayakhlang clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT farahalbader clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT petraagolovics clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT gustavodrugghahn clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT talatbessissow clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT alainbitton clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT waqqasafif clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT garywild clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease AT peterllakatos clinicaloutcomesofcovid19andimpactondiseasecourseinpatientswithinflammatoryboweldisease |